CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Pegasys (peginterferon alfa-2a) — Coverage Criteria for Hematologic Indications

Defines accepted indications, contraindications, exclusions, coding, and clinical evidence sources for use of Pegasys (peginterferon alfa-2a) in hematologic malignancies for members whose medication requests are processed by Evolent for Neighborhood Health Plan of Rhode Island.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyPegasys (peginterferon alfa-2a) — Coverage Criteria for Hematologic Indications

Policy CodePolicy N/A

Change TypeTemplate conversion / operational revision

Effective DateN/A

Next Review DateN/A

Key ActionSubmit authorization requests to Evolent with supporting evidence from FDA labeling, CMS-recognized compendia, NCCN/ASCO guidelines, or acceptable peer-reviewed literature.

SourceLink

POLICY UPDATE CHANGES

Converted to new Evolent guideline template and replaced prior UM ONC_1497 Pegasys guideline.

3hematologic indications listed (PMF, PV, ET)

180 mcgsingle dose maximum excluded

J3590listed billing code for peginterferon alfa-2a

Commercial/Exchange/Medicaidlines of business

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Primary myelofibrosis (PMF)

Covered when ANY of the following disease-specific conditions are met:

Disease indications: Pegasys may be used as first-line or subsequent therapy for members with low-risk primary myelofibrosis (PMF)

Polycythemia vera (PV)

Polycythemia vera: Pegasys may be used as first-line or subsequent therapy for members with symptomatic low-risk polycythemia vera or high-risk polycythemia vera

Essential thrombocythemia (ET)

Essential thrombocythemia: Pegasys may be used as subsequent therapy for members with intermediate- or high-risk essential thrombocythemia

Requests for Pegasys (peginterferon alfa-2a) will be excluded or denied when any of the following operational limits apply. Coverage is not approved for members who have experienced disease progression while taking Pegasys. Concurrent administration with other anticancer therapies is not allowed; combination use with chemotherapy, biologic, immune, targeted, or other oncologic therapies will be denied. Dosing requests that exceed a single dose of 180 mcg are outside the allowable limit and will be rejected. Finally, requests for indications considered investigational or off‑label that lack sufficient supporting evidence per the policy (see standards for acceptable evidence) are not approvable.

Use of Pegasys for investigational or off‑label indications that are not generally accepted by the medical community is considered not medically necessary and will not be approved. The policy requires that off‑label uses be supported by adequate evidence as defined in the guideline, including representation of the patient and disease in published studies, appropriate therapeutic regimens in the evidence base, and clinically meaningful outcomes (for example, ASCO‑recommended thresholds such as a hazard ratio < 0.80 or survival benefit of at least 3 months for OS/PFS). Lower‑quality sources (case reports, meeting abstracts without full peer‑reviewed articles) generally do not meet the evidence threshold; nonrandomized trials with substantial subject numbers may be supportive when appropriate.

Authorization, Documentation, and Denial Risk

Prior Authorization

Authorization and continuation requirements

All medication requests for Pegasys (peginterferon alfa-2a) are processed by Evolent and require prior authorization. Continuation requests may be exempt from a new authorization if the member has not experienced disease progression on Pegasys, the medication was used within the last year without a lapse of more than 30 days of an active authorization, and no additional medications are being added to the continuation request.

Prior authorization is required for all new medication requests processed by Evolent.
Continuation requests are exempt when: no disease progression on the medication; prior use within last year without >30-day lapse; and no additional medications are added.

Step Therapy

Step therapy not defined

The guideline does not define a step-therapy sequence or prerequisite therapies; allowed use is described by disease setting (PMF, PV, ET) without a required stepwise trial of other agents.

Documentation Required

Evidence documentation required

Use must be supported by one of the following sources: FDA-approved product labeling, CMS-recognized compendia, NCCN or ASCO clinical guidelines, or peer-reviewed literature that meets CMS Medicare Benefit Policy Manual Chapter 15 requirements. References and supporting literature are listed in the guideline.

Acceptable evidence sources: FDA labeling; CMS-approved compendia; NCCN; ASCO; peer‑reviewed literature meeting CMS Chapter 15 standards.

Denial Risk

Exclusion grounds that trigger denial

Requests will be excluded or denied for the following: disease progression while taking Pegasys; concurrent use with other anticancer therapies; dosing that exceeds the single dose limit of 180 mcg; or investigational/off-label indications that lack sufficient evidence per CMS-recognized compendia or acceptable peer‑reviewed literature.

Disease progression on Pegasys is a denial trigger.
Concurrent use with other anticancer therapies is excluded.
Dosing that exceeds a single dose of 180 mcg will be denied.
Off-label investigational uses lacking sufficient evidence per CMS compendia or acceptable peer‑reviewed literature are not approvable.

Line of Therapy Designations

first-line

First-line (PMF): Pegasys may be used as first-line or subsequent therapy for low-risk primary myelofibrosis

first-line

First-line (PV): Pegasys may be used as first-line or subsequent therapy for symptomatic low-risk or high-risk polycythemia vera

second-line

Second-line (ET): Pegasys may be used as subsequent therapy for members with intermediate- or high-risk essential thrombocythemia

Indication Definitions

Primary myelofibrosis (PMF)

IndicationPrimary myelofibrosis (PMF)

Coverage statementPegasys (peginterferon alfa-2a) may be used as first-line or subsequent therapy for members with low‑risk myelofibrosis.

Line of therapyFirst-line or subsequent therapy for low-risk PMF

Polycythemia vera (PV)

IndicationPolycythemia vera (PV)

Coverage statementPegasys (peginterferon alfa-2a) may be used as first-line or subsequent therapy for members with symptomatic low‑risk or high‑risk polycythemia vera.

Line of therapyFirst-line or subsequent therapy for symptomatic low‑risk or high‑risk PV

Essential thrombocythemia (ET)

IndicationEssential thrombocythemia (ET)

Coverage statementPegasys (peginterferon alfa-2a) may be used as subsequent therapy for members with intermediate‑ or high‑risk essential thrombocythemia.

Line of therapySubsequent therapy for intermediate/high‑risk ET

Background and Clinical Context

Peginterferon alfa‑2a (Pegasys) is a pegylated interferon indicated in this guideline for selected myeloproliferative neoplasms. The policy supports use of Pegasys as first‑line or subsequent therapy for low‑risk primary myelofibrosis (PMF), as first‑line or subsequent therapy for symptomatic low‑risk or high‑risk polycythemia vera (PV), and as subsequent therapy for intermediate‑ or high‑risk essential thrombocythemia (ET). The guideline also highlights important safety and exclusion considerations (see exclusions), and requires that use be supported by appropriate clinical evidence and documentation.